Browsing by Author "Ruiz-Garcia, Erika"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Publication Gender Disparities in Oncology: A Report From Four Countries in Latin America(2025) Ismael, Julia; Montenegro, Paola; Müller, Bettina; Barragan-Carrillo, Regina; Hernández-Marín, Jazmin; Fernández-Figueroa, Edith A.; Argueta-Donohué, Jesús; Ruiz-Garcia, ErikaPurpose: Women represent a growing force in oncology but remain underrepresented in high-level positions. Gender-related challenges affect academic progression, research, and clinical practice. This manuscript aims to describes gender-based professional development challenges faced by women in oncology in Latin America (LATAM). Materials and methods: We conducted a multicenter, cross-sectional study among LATAM oncologists using a 27-item questionnaire on the basis of the European Society for Medical Oncology Women for Oncology Survey. Our analysis focused on male-female disparities, excluding other gender identities. Logistic regression models were used to calculated odds ratios (ORs) for gender inequity, wage disparity, workplace and sexual harassment, and family development. Statistical analyses were performed using SPSS version 26, with the significance set at P < .05. Results: We analyzed 254 participants from Argentina, Chile, Mexico, and Peru, mostly females (88%) and based in Mexico (55%). Most were attending physicians (68%), 51.5% worked 41-60 hours, and 33.4% reported gender equity initiatives. Gender inequity was significantly higher among women (83%) than among men (37%), with the female gender identified as a risk factor (OR, 15.67; P < .001). Workplace harassment was reported by 60% of women and 19% of men, whereas sexual harassment was experienced by 34% of women and 16% of men (OR, 2.78; P < .05). Sixty-five percent reported that men had the highest salaries. Logistic regression indicated that working 20-40 hours per week was associated with the likelihood of women having children (OR, 3.0; P < .01), as was working 41-60 hours (OR, 1.97; P < .01). However, holding an attending or resident position was associated with significantly lower childbearing rates. Conclusion: Our findings indicate that Women oncologists in LATAM report experiencing higher rates of gender-based inequity and harassment and remain underrepresented in leadership and high-earning roles.Publication Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries(2024) Medel-Jara, Patricio; Reyes Placencia, Diego; Fuentes-López, Eduardo; Corsi, Oscar; Latorre, Gonzalo; Antón, Rosario; Jiménez, Elena; Miralles-Marco, Ana; Caballero, Carmelo; Boggino, Hugo; Cantero, Daniel; Barros, Rita; Santos-Antunes, João; Díez, Marc; Quiñones, Luis A.; Riquelme, Erick; Rollan, Antonio; Cerpa, Leslie C.; Valdés, Ivania; Nyssen, Olga P.; Moreira, Leticia; Gisbert, Javier P.; Camargo, M. Constanza; Ortiz-Olvera, Nayeli; Leon‐Takahashi, Alberto, M.; Ruiz-Garcia, Erika; Fernández-Figueroa, Edith A.; Garrido, Marcelo; Owen, Gareth I.; Cervantes, Andrés; Fleita, Tania; Riquelme, ArnoldoIntroduction: Gastric cancer (GC) is one of the most lethal malignancies worldwide.Helicobacter pylori is the primary cause of GC; therefore, its eradication reduces therisk of developing this neoplasia. There is extensive evidence regarding quadrupletherapy with relevance to the European population. However, in Latin America, dataare scarce. Furthermore, there is limited information about the eradication ratesachieved by antibiotic schemes in European and Latin American populations.Objective: To compare the effectiveness of standard triple therapy (STT), quadrupleconcomitant therapy (QCT), and bismuth quadruple therapy (QBT) in six centers inEurope and Latin America.Methods: A retrospective study was carried out based on the LEGACy registry from2017 to 2022. Data from adult patients recruited in Portugal, Spain, Chile, Mexico,and Paraguay with confirmed H. pylori infection who received eradication therapyand confirmatory tests at least 1 month apart were included. Treatment success by each scheme was compared using a mixed multilevel Poisson regression, adjustingfor patient sex and age, together with country‐specific variables, including preva-lence of H. pylori antibiotic resistance (clarithromycin, metronidazole, and amoxi-cillin), and CYP2C19 polymorphisms.Results: 772 patients were incorporated (64.64% females; mean age of 52.93 years).The total H. pylori eradication rates were 75.20% (255/339) with STT, 88.70% (159/178) with QCT, and 91.30% (191/209) with QBT. Both quadruple therapies (QCT‐QBT) showed significantly higher eradication rates compared with STT, with anadjusted incidence risk ratio (IRR) of 1.25 (p: <0.05); and 1.24 (p: <0.05), respectively.The antibiotic‐resistance prevalence by country, but not the prevalence of CYP2C19polymorphism, showed a statistically significant impact on eradication success.Conclusions: Both QCT and QBT are superior to STT for H. pylori eradication whenadjusted for country‐specific antibiotic resistance and CYP2C19 polymorphism in asample of individuals residing in five countries within two continents.